S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Will This Be the Worst U.S. Crisis Ever? (Ad)
NASDAQ:OPK

OPKO Health - OPK Stock Forecast, Price & News

$2.45
+0.17 (+7.46%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.30
$2.46
50-Day Range
$2.28
$3.09
52-Week Range
$2.15
$5.25
Volume
6.04 million shs
Average Volume
4.54 million shs
Market Capitalization
$1.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

OPKO Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
104.1% Upside
$5.00 Price Target
Short Interest
Bearish
15.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
-0.49mentions of OPKO Health in the last 14 days
Based on 11 Articles This Week
Insider Trading
Acquiring Shares
$5.48 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.22) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

628th out of 1,293 stocks

Pharmaceutical Preparations Industry

298th out of 619 stocks

OPK stock logo

About OPKO Health (NASDAQ:OPK) Stock

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler cut their price target on OPKO Health from $5.00 to $4.00 and set an "overweight" rating on the stock in a report on Friday.

OPKO Health Stock Performance

OPKO Health stock opened at $2.45 on Tuesday. The company has a market capitalization of $1.67 billion, a PE ratio of -8.45 and a beta of 1.75. The firm has a fifty day simple moving average of $2.60 and a two-hundred day simple moving average of $2.97. The company has a quick ratio of 1.91, a current ratio of 2.30 and a debt-to-equity ratio of 0.12. OPKO Health has a twelve month low of $2.15 and a twelve month high of $5.25.

OPKO Health (NASDAQ:OPK - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.12). The firm had revenue of $309.90 million for the quarter, compared to analysts' expectations of $326.87 million. OPKO Health had a negative net margin of 14.18% and a negative return on equity of 7.72%. The company's quarterly revenue was down 30.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.03) EPS. Research analysts expect that OPKO Health will post -0.22 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost bought 350,000 shares of the business's stock in a transaction that occurred on Friday, August 5th. The stock was bought at an average cost of $2.29 per share, with a total value of $801,500.00. Following the completion of the purchase, the chief executive officer now owns 196,956,694 shares of the company's stock, valued at approximately $451,030,829.26. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 350,000 shares of the company's stock in a transaction on Friday, August 5th. The stock was acquired at an average cost of $2.29 per share, with a total value of $801,500.00. Following the purchase, the chief executive officer now directly owns 196,956,694 shares of the company's stock, valued at approximately $451,030,829.26. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Gary J. Nabel bought 240,000 shares of the stock in a transaction dated Wednesday, June 22nd. The stock was purchased at an average price of $2.49 per share, with a total value of $597,600.00. Following the acquisition, the insider now directly owns 19,857,514 shares in the company, valued at approximately $49,445,209.86. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 1,590,000 shares of company stock worth $4,114,100. Company insiders own 40.97% of the company's stock.

Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

OPK Stock News Headlines

Earnings Outlook For OPKO Health
OPKO Health (NASDAQ:OPK) Stock Price Down 3.3%
OPK July 22nd Options Begin Trading
Why Opko Health Stock Is Jumping Today
OPKO Health Misses Q1 EPS by 2c
See More Headlines
Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

OPK Company Calendar

Last Earnings
8/04/2022
Today
8/09/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:OPK
CUSIP
68375N10
Employees
5,767
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+104.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-30,140,000.00
Pretax Margin
-13.83%

Debt

Sales & Book Value

Annual Sales
$1.77 billion
Cash Flow
$0.08 per share
Book Value
$2.47 per share

Miscellaneous

Free Float
455,688,000
Market Cap
$1.67 billion
Optionable
Optionable
Beta
1.75

Key Executives

  • Dr. Phillip Frost Ph.D. (Age 86)
    Chairman & CEO
    Comp: $971.6k
  • Dr. Jane H. Hsiao M.B.A. (Age 75)
    MBA, Ph.D., Vice Chairman & Chief Technical Officer
    Comp: $911.6k
  • Mr. Adam E. Logal (Age 44)
    Sr. VP, CFO, Chief Accounting Officer & Treasurer
    Comp: $911.6k
  • Mr. Steven D. Rubin Esq. (Age 62)
    J.D., Exec. VP of Admin. & Director
    Comp: $821.6k
  • Dr. Jon R. Cohen M.D. (Age 67)
    Sr. VP & Director
    Comp: $1.74M
  • Dr. Elias Adam Zerhouni M.D. (Age 71)
    Pres & Vice Chairman
  • Dr. Arie Gutman (Age 68)
    Pres of API
  • Mr. James DeMarco
    Sr. VP of Pharmaceutical Sales
  • Dr. Akhtar Ashfaq
    Sr. VP of Clinical R&D and Medical Affairs
  • Ms. Jane Pine Wood Esq. (Age 59)
    J.D., Chief Legal Officer of Bio-Reference Laboratories













OPK Stock - Frequently Asked Questions

Should I buy or sell OPKO Health stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" OPK shares.
View OPK analyst ratings
or view top-rated stocks.

What is OPKO Health's stock price forecast for 2022?

2 Wall Street analysts have issued 12-month price targets for OPKO Health's shares. Their OPK share price forecasts range from $4.00 to $6.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 104.1% from the stock's current price.
View analysts price targets for OPK
or view top-rated stocks among Wall Street analysts.

How has OPKO Health's stock price performed in 2022?

OPKO Health's stock was trading at $4.81 at the start of the year. Since then, OPK shares have decreased by 49.1% and is now trading at $2.45.
View the best growth stocks for 2022 here
.

When is OPKO Health's next earnings date?

OPKO Health is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our OPK earnings forecast
.

How were OPKO Health's earnings last quarter?

OPKO Health, Inc. (NASDAQ:OPK) posted its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.12. The biotechnology company earned $309.90 million during the quarter, compared to analyst estimates of $326.87 million. OPKO Health had a negative trailing twelve-month return on equity of 7.72% and a negative net margin of 14.18%. The company's revenue was down 30.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.03) earnings per share.

What is Philip Frost's approval rating as OPKO Health's CEO?

21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OPKO Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

What is OPKO Health's stock symbol?

OPKO Health trades on the NASDAQ under the ticker symbol "OPK."

Who are OPKO Health's major shareholders?

OPKO Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wolverine Asset Management LLC (0.00%), Trellus Management Company LLC (0.09%), Connor Clark & Lunn Investment Management Ltd. (0.08%), State Board of Administration of Florida Retirement System (0.05%), Victory Capital Management Inc. (0.05%) and Hennion & Walsh Asset Management Inc. (0.02%). Insiders that own company stock include Anthony J Japour, Elias A Zerhouni, Gary J Nabel, Jane Ph D Hsiao, Jon R Cohen, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert J Shovlin and Steven D Rubin.
View institutional ownership trends
.

How do I buy shares of OPKO Health?

Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OPKO Health's stock price today?

One share of OPK stock can currently be purchased for approximately $2.45.

How much money does OPKO Health make?

OPKO Health (NASDAQ:OPK) has a market capitalization of $1.67 billion and generates $1.77 billion in revenue each year. The biotechnology company earns $-30,140,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does OPKO Health have?

OPKO Health employs 5,767 workers across the globe.

How can I contact OPKO Health?

OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The official website for the company is www.opko.com. The biotechnology company can be reached via phone at (305) 575-4100, via email at mmiller@lhai.com, or via fax at 305-575-6015.

This page (NASDAQ:OPK) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.